JP7039037B2 - 腫瘍の治療および／または阻止において使用するためのアレナウイルス（ａｒｅｎａｖｉｒｕｓｅｓ）、および、（改善された）腫瘍退縮特性（ｔｕｍｏｒ－ｒｅｇｒｅｓｓｉｏｎ ｐｒｏｐｅｒｔｉｅｓ）を有するアレナウイルス（ａｒｅｎａｖｉｒｕｓｅｓ）を産生するための方法 - Google Patents
腫瘍の治療および／または阻止において使用するためのアレナウイルス（ａｒｅｎａｖｉｒｕｓｅｓ）、および、（改善された）腫瘍退縮特性（ｔｕｍｏｒ－ｒｅｇｒｅｓｓｉｏｎ ｐｒｏｐｅｒｔｉｅｓ）を有するアレナウイルス（ａｒｅｎａｖｉｒｕｓｅｓ）を産生するための方法 Download PDFInfo
- Publication number
- JP7039037B2 JP7039037B2 JP2018505536A JP2018505536A JP7039037B2 JP 7039037 B2 JP7039037 B2 JP 7039037B2 JP 2018505536 A JP2018505536 A JP 2018505536A JP 2018505536 A JP2018505536 A JP 2018505536A JP 7039037 B2 JP7039037 B2 JP 7039037B2
- Authority
- JP
- Japan
- Prior art keywords
- tumor
- cells
- arenavirus
- arenaviruses
- virus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 241000712891 Arenavirus Species 0.000 title claims description 180
- 206010028980 Neoplasm Diseases 0.000 title claims description 142
- 238000000034 method Methods 0.000 title description 29
- 230000005764 inhibitory process Effects 0.000 title description 5
- 241000712899 Lymphocytic choriomeningitis mammarenavirus Species 0.000 claims description 82
- 241000700605 Viruses Species 0.000 claims description 52
- 201000011510 cancer Diseases 0.000 claims description 25
- 201000001441 melanoma Diseases 0.000 claims description 20
- 206010039491 Sarcoma Diseases 0.000 claims description 17
- 206010025323 Lymphomas Diseases 0.000 claims description 12
- 201000009030 Carcinoma Diseases 0.000 claims description 11
- 239000003795 chemical substances by application Substances 0.000 claims description 9
- 230000000527 lymphocytic effect Effects 0.000 claims description 9
- 201000000053 blastoma Diseases 0.000 claims description 8
- 201000008184 embryoma Diseases 0.000 claims description 8
- 210000002865 immune cell Anatomy 0.000 claims description 8
- 229940079593 drug Drugs 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 7
- 102000006992 Interferon-alpha Human genes 0.000 claims description 6
- 108010047761 Interferon-alpha Proteins 0.000 claims description 6
- 241001244466 New world arenaviruses Species 0.000 claims description 6
- 241001244462 Old world arenaviruses Species 0.000 claims description 6
- 230000028327 secretion Effects 0.000 claims description 6
- 206010010356 Congenital anomaly Diseases 0.000 claims description 3
- 102000008070 Interferon-gamma Human genes 0.000 claims description 3
- 108010074328 Interferon-gamma Proteins 0.000 claims description 3
- 210000000481 breast Anatomy 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 229960003130 interferon gamma Drugs 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 102000003996 Interferon-beta Human genes 0.000 claims 1
- 108090000467 Interferon-beta Proteins 0.000 claims 1
- 229960001388 interferon-beta Drugs 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 96
- 241000699670 Mus sp. Species 0.000 description 45
- 210000004881 tumor cell Anatomy 0.000 description 42
- 241001465754 Metazoa Species 0.000 description 40
- 229920002477 rna polymer Polymers 0.000 description 32
- 210000004443 dendritic cell Anatomy 0.000 description 31
- 230000037396 body weight Effects 0.000 description 24
- 230000004083 survival effect Effects 0.000 description 24
- 210000001744 T-lymphocyte Anatomy 0.000 description 13
- 238000011579 SCID mouse model Methods 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 10
- 239000002245 particle Substances 0.000 description 10
- 201000008808 Fibrosarcoma Diseases 0.000 description 9
- 230000004614 tumor growth Effects 0.000 description 9
- 208000025188 carcinoma of pharynx Diseases 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 230000003612 virological effect Effects 0.000 description 7
- 241000712890 Junin mammarenavirus Species 0.000 description 6
- 206010027476 Metastases Diseases 0.000 description 6
- 108091028043 Nucleic acid sequence Proteins 0.000 description 6
- 210000000234 capsid Anatomy 0.000 description 6
- 238000004113 cell culture Methods 0.000 description 6
- 210000002540 macrophage Anatomy 0.000 description 6
- 230000035772 mutation Effects 0.000 description 6
- 150000007523 nucleic acids Chemical group 0.000 description 6
- 230000010076 replication Effects 0.000 description 6
- 201000009695 Argentine hemorrhagic fever Diseases 0.000 description 5
- 206010009944 Colon cancer Diseases 0.000 description 5
- 241000190708 Guanarito mammarenavirus Species 0.000 description 5
- 206010021143 Hypoxia Diseases 0.000 description 5
- 241000712902 Lassa mammarenavirus Species 0.000 description 5
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 5
- 241000785917 Savia Species 0.000 description 5
- 241000205658 Whitewater Arroyo mammarenavirus Species 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 238000001990 intravenous administration Methods 0.000 description 5
- 201000005202 lung cancer Diseases 0.000 description 5
- 208000020816 lung neoplasm Diseases 0.000 description 5
- 238000007920 subcutaneous administration Methods 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 4
- 206010006187 Breast cancer Diseases 0.000 description 4
- 208000026310 Breast neoplasm Diseases 0.000 description 4
- 206010008342 Cervix carcinoma Diseases 0.000 description 4
- 241000190598 Flexal mammarenavirus Species 0.000 description 4
- 206010019695 Hepatic neoplasm Diseases 0.000 description 4
- 241000190596 Latino mammarenavirus Species 0.000 description 4
- 241000712898 Machupo mammarenavirus Species 0.000 description 4
- 241000146363 Oliveros mammarenavirus Species 0.000 description 4
- 208000009565 Pharyngeal Neoplasms Diseases 0.000 description 4
- 206010034811 Pharyngeal cancer Diseases 0.000 description 4
- 241000712910 Pichinde mammarenavirus Species 0.000 description 4
- 206010060862 Prostate cancer Diseases 0.000 description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 4
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 201000010881 cervical cancer Diseases 0.000 description 4
- 208000029742 colonic neoplasm Diseases 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 229940124590 live attenuated vaccine Drugs 0.000 description 4
- 229940023012 live-attenuated vaccine Drugs 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- 238000007910 systemic administration Methods 0.000 description 4
- 210000002845 virion Anatomy 0.000 description 4
- WVWOOAYQYLJEFD-UHFFFAOYSA-N 1-(2-nitroimidazol-1-yl)-3-piperidin-1-ylpropan-2-ol Chemical class C1=CN=C([N+]([O-])=O)N1CC(O)CN1CCCCC1 WVWOOAYQYLJEFD-UHFFFAOYSA-N 0.000 description 3
- 241001295068 Allpahuayo mammarenavirus Species 0.000 description 3
- 241000190711 Amapari mammarenavirus Species 0.000 description 3
- 206010061424 Anal cancer Diseases 0.000 description 3
- 201000003076 Angiosarcoma Diseases 0.000 description 3
- 208000007860 Anus Neoplasms Diseases 0.000 description 3
- 241001244472 Cupixi mammarenavirus Species 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 208000006168 Ewing Sarcoma Diseases 0.000 description 3
- 208000001258 Hemangiosarcoma Diseases 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 241000555269 Ippy mammarenavirus Species 0.000 description 3
- 208000006644 Malignant Fibrous Histiocytoma Diseases 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 206010033128 Ovarian cancer Diseases 0.000 description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 3
- 241000190594 Parana mammarenavirus Species 0.000 description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 description 3
- 241000190592 Tamiami mammarenavirus Species 0.000 description 3
- 208000024313 Testicular Neoplasms Diseases 0.000 description 3
- 206010057644 Testis cancer Diseases 0.000 description 3
- 208000024770 Thyroid neoplasm Diseases 0.000 description 3
- 208000015778 Undifferentiated pleomorphic sarcoma Diseases 0.000 description 3
- 230000003044 adaptive effect Effects 0.000 description 3
- 201000011165 anus cancer Diseases 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 238000002659 cell therapy Methods 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 206010017758 gastric cancer Diseases 0.000 description 3
- 230000001146 hypoxic effect Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 208000014018 liver neoplasm Diseases 0.000 description 3
- 239000006166 lysate Substances 0.000 description 3
- 201000009020 malignant peripheral nerve sheath tumor Diseases 0.000 description 3
- 208000029974 neurofibrosarcoma Diseases 0.000 description 3
- 201000008968 osteosarcoma Diseases 0.000 description 3
- 201000002528 pancreatic cancer Diseases 0.000 description 3
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 3
- 210000003705 ribosome Anatomy 0.000 description 3
- 208000002491 severe combined immunodeficiency Diseases 0.000 description 3
- 201000011549 stomach cancer Diseases 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 201000003120 testicular cancer Diseases 0.000 description 3
- 201000002510 thyroid cancer Diseases 0.000 description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- 241001440626 Bear Canyon mammarenavirus Species 0.000 description 2
- FGUUSXIOTUKUDN-IBGZPJMESA-N C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 Chemical compound C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 FGUUSXIOTUKUDN-IBGZPJMESA-N 0.000 description 2
- 208000005243 Chondrosarcoma Diseases 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 206010061192 Haemorrhagic fever Diseases 0.000 description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 description 2
- 206010023825 Laryngeal cancer Diseases 0.000 description 2
- 241001573276 Lujo mammarenavirus Species 0.000 description 2
- 238000011789 NOD SCID mouse Methods 0.000 description 2
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 description 2
- 206010038389 Renal cancer Diseases 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 241000712908 Tacaribe mammarenavirus Species 0.000 description 2
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 2
- 108020000999 Viral RNA Proteins 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000006978 adaptation Effects 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 210000000941 bile Anatomy 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000001415 gene therapy Methods 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 201000010982 kidney cancer Diseases 0.000 description 2
- 206010023841 laryngeal neoplasm Diseases 0.000 description 2
- 206010024627 liposarcoma Diseases 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 210000002752 melanocyte Anatomy 0.000 description 2
- 210000004088 microvessel Anatomy 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000007491 morphometric analysis Methods 0.000 description 2
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 229950010456 pimonidazole Drugs 0.000 description 2
- 230000008092 positive effect Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 239000004576 sand Substances 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 102100023990 60S ribosomal protein L17 Human genes 0.000 description 1
- 208000006740 Aseptic Meningitis Diseases 0.000 description 1
- 206010061692 Benign muscle neoplasm Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241000659008 Chapare mammarenavirus Species 0.000 description 1
- 208000002691 Choroiditis Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 101001065501 Escherichia phage MS2 Lysis protein Proteins 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000010789 Interleukin-2 Receptors Human genes 0.000 description 1
- 108010038453 Interleukin-2 Receptors Proteins 0.000 description 1
- 102000010782 Interleukin-7 Receptors Human genes 0.000 description 1
- 108010038498 Interleukin-7 Receptors Proteins 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 208000018142 Leiomyosarcoma Diseases 0.000 description 1
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 206010027201 Meningitis aseptic Diseases 0.000 description 1
- 241000555271 Mobala mammarenavirus Species 0.000 description 1
- 201000004458 Myoma Diseases 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 241000245926 Pirital mammarenavirus Species 0.000 description 1
- 208000003971 Posterior uveitis Diseases 0.000 description 1
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 206010039509 Scab Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 206010043515 Throat cancer Diseases 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- 208000035472 Zoonoses Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 210000005006 adaptive immune system Anatomy 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 238000002619 cancer immunotherapy Methods 0.000 description 1
- 210000003321 cartilage cell Anatomy 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 239000002771 cell marker Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 108091092328 cellular RNA Proteins 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000004922 colonic epithelial cell Anatomy 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 210000000448 cultured tumor cell Anatomy 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000014541 detection of hypoxia Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 201000003914 endometrial carcinoma Diseases 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- MUJOIMFVNIBMKC-UHFFFAOYSA-N fludioxonil Chemical compound C=12OC(F)(F)OC2=CC=CC=1C1=CNC=C1C#N MUJOIMFVNIBMKC-UHFFFAOYSA-N 0.000 description 1
- 201000010175 gallbladder cancer Diseases 0.000 description 1
- 201000007487 gallbladder carcinoma Diseases 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 230000003447 ipsilateral effect Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 210000004779 membrane envelope Anatomy 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 239000003471 mutagenic agent Substances 0.000 description 1
- 231100000707 mutagenic chemical Toxicity 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- 230000000869 mutational effect Effects 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 208000020668 oropharyngeal carcinoma Diseases 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 230000001373 regressive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 108020004418 ribosomal RNA Proteins 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 206010048282 zoonosis Diseases 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/10011—Arenaviridae
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/10011—Arenaviridae
- C12N2760/10021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/10011—Arenaviridae
- C12N2760/10032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/10011—Arenaviridae
- C12N2760/10033—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Oncology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021088871A JP7273102B2 (ja) | 2015-04-17 | 2021-05-27 | 腫瘍の治療および／または阻止において使用するためのアレナウイルス（ａｒｅｎａｖｉｒｕｓｅｓ）、および、（改善された）腫瘍退縮特性（ｔｕｍｏｒ－ｒｅｇｒｅｓｓｉｏｎ ｐｒｏｐｅｒｔｉｅｓ）を有するアレナウイルス（ａｒｅｎａｖｉｒｕｓｅｓ）を産生するための方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102015207036.0 | 2015-04-17 | ||
| DE102015207036.0A DE102015207036A1 (de) | 2015-04-17 | 2015-04-17 | Arenaviren zur Anwendung bei der Behandlung und/oder Vorbeugung von Tumoren sowie Verfahren zur Herstellung von Arenaviren mit (verbesserten) tumorregressiven Eigenschaften |
| PCT/EP2016/058347 WO2016166285A1 (de) | 2015-04-17 | 2016-04-15 | Arenaviren zur anwendung bei der behandlung und/oder vorbeugung von tumoren sowie verfahren zur herstellung von arenaviren mit (verbesserten) tumorregressiven eigenschaften |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021088871A Division JP7273102B2 (ja) | 2015-04-17 | 2021-05-27 | 腫瘍の治療および／または阻止において使用するためのアレナウイルス（ａｒｅｎａｖｉｒｕｓｅｓ）、および、（改善された）腫瘍退縮特性（ｔｕｍｏｒ－ｒｅｇｒｅｓｓｉｏｎ ｐｒｏｐｅｒｔｉｅｓ）を有するアレナウイルス（ａｒｅｎａｖｉｒｕｓｅｓ）を産生するための方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018515130A JP2018515130A (ja) | 2018-06-14 |
| JP2018515130A5 JP2018515130A5 (enExample) | 2019-05-23 |
| JP7039037B2 true JP7039037B2 (ja) | 2022-03-22 |
Family
ID=55759589
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018505536A Active JP7039037B2 (ja) | 2015-04-17 | 2016-04-15 | 腫瘍の治療および／または阻止において使用するためのアレナウイルス（ａｒｅｎａｖｉｒｕｓｅｓ）、および、（改善された）腫瘍退縮特性（ｔｕｍｏｒ－ｒｅｇｒｅｓｓｉｏｎ ｐｒｏｐｅｒｔｉｅｓ）を有するアレナウイルス（ａｒｅｎａｖｉｒｕｓｅｓ）を産生するための方法 |
| JP2021088871A Active JP7273102B2 (ja) | 2015-04-17 | 2021-05-27 | 腫瘍の治療および／または阻止において使用するためのアレナウイルス（ａｒｅｎａｖｉｒｕｓｅｓ）、および、（改善された）腫瘍退縮特性（ｔｕｍｏｒ－ｒｅｇｒｅｓｓｉｏｎ ｐｒｏｐｅｒｔｉｅｓ）を有するアレナウイルス（ａｒｅｎａｖｉｒｕｓｅｓ）を産生するための方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021088871A Active JP7273102B2 (ja) | 2015-04-17 | 2021-05-27 | 腫瘍の治療および／または阻止において使用するためのアレナウイルス（ａｒｅｎａｖｉｒｕｓｅｓ）、および、（改善された）腫瘍退縮特性（ｔｕｍｏｒ－ｒｅｇｒｅｓｓｉｏｎ ｐｒｏｐｅｒｔｉｅｓ）を有するアレナウイルス（ａｒｅｎａｖｉｒｕｓｅｓ）を産生するための方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US20180117137A1 (enExample) |
| EP (1) | EP3283104B1 (enExample) |
| JP (2) | JP7039037B2 (enExample) |
| CN (1) | CN108025054B (enExample) |
| CA (1) | CA2982873A1 (enExample) |
| DE (1) | DE102015207036A1 (enExample) |
| ES (1) | ES3017684T3 (enExample) |
| WO (1) | WO2016166285A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3218504B1 (en) | 2014-11-13 | 2020-07-22 | Université de Genève | Tri-segmented arenaviruses as vaccine vectors |
| DE102015207036A1 (de) | 2015-04-17 | 2016-10-20 | Karl Sebastian Lang | Arenaviren zur Anwendung bei der Behandlung und/oder Vorbeugung von Tumoren sowie Verfahren zur Herstellung von Arenaviren mit (verbesserten) tumorregressiven Eigenschaften |
| CA2987155A1 (en) | 2015-06-10 | 2016-12-15 | Hookipa Biotech Ag | Hpv vaccines |
| CA3003557A1 (en) | 2015-11-04 | 2017-05-11 | Hookipa Biotech Ag | Vaccines against hepatitis b virus |
| US11266727B2 (en) | 2015-11-12 | 2022-03-08 | Hookipa Biotech Gmbh | Arenavirus particles as cancer vaccines |
| EP3606549A1 (en) * | 2017-04-07 | 2020-02-12 | Hookipa Biotech GmbH | Arenavirus particles to treat solid tumors |
| DE102018215551A1 (de) * | 2018-09-12 | 2020-03-12 | Virolutions Biotech Gmbh | Verfahren zur Herstellung eines antitumoralen Arenavirus sowie Arenavirusmutanten |
| WO2022180203A1 (en) | 2021-02-26 | 2022-09-01 | Abalos Therapeutics Gmbh | New virus particles for therapeutic purposes |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102004034461B4 (de) | 2004-07-16 | 2008-02-07 | Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus | Gentherapie solider Tumore durch retrovirale, mit Arenavirus-Glykoprotein pseudotypisierte Vektoren |
| US7994221B2 (en) | 2004-12-06 | 2011-08-09 | Siga Technologies, Inc. | Sulfonyl semicarbazides, carbonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with arenaviruses |
| CN103255169A (zh) | 2007-12-27 | 2013-08-21 | 苏黎士大学 | 复制缺陷型沙粒病毒载体 |
| WO2011056993A1 (en) * | 2009-11-04 | 2011-05-12 | Yale University | Compositions and methods for treating cancer with attenuated oncolytic viruses |
| DE102015207036A1 (de) | 2015-04-17 | 2016-10-20 | Karl Sebastian Lang | Arenaviren zur Anwendung bei der Behandlung und/oder Vorbeugung von Tumoren sowie Verfahren zur Herstellung von Arenaviren mit (verbesserten) tumorregressiven Eigenschaften |
-
2015
- 2015-04-17 DE DE102015207036.0A patent/DE102015207036A1/de active Pending
-
2016
- 2016-04-15 JP JP2018505536A patent/JP7039037B2/ja active Active
- 2016-04-15 CN CN201680030624.5A patent/CN108025054B/zh active Active
- 2016-04-15 WO PCT/EP2016/058347 patent/WO2016166285A1/de not_active Ceased
- 2016-04-15 EP EP16717129.7A patent/EP3283104B1/de active Active
- 2016-04-15 US US15/567,343 patent/US20180117137A1/en not_active Abandoned
- 2016-04-15 CA CA2982873A patent/CA2982873A1/en active Pending
- 2016-04-15 ES ES16717129T patent/ES3017684T3/es active Active
-
2019
- 2019-02-04 US US16/267,095 patent/US11801294B2/en active Active
-
2021
- 2021-05-27 JP JP2021088871A patent/JP7273102B2/ja active Active
-
2023
- 2023-10-30 US US18/385,250 patent/US12409217B2/en active Active
Non-Patent Citations (10)
| Title |
|---|
| Cancer Res.，2015年04月15日，vol. 74, no. 8，p. 2171-2181 |
| ELIZABETH, Kelly and STEPHEN J. Russell，HISTORY OF ONCOLYTIC VIRUSES: GENESIS TO GENETIC ENGINEERING，MOLECULAR THERAPY，2007年，VOLUME 15, ISSUE 4，P651-659 |
| GONI, S.E. et al.，Genomic features of attenuated Junin virus vaccine strain candidate，Virus Genes，2006年，32(1)，37-41 |
| HONKE, Nadine et al.，Usp18 driven enforced viral replication in dendritic cells contributes to break of immunological tolerance in autoimmune diabetes.，PLoS Pathog.，2013年，9(10)，e1003650 |
| KOMA, Takaaki et al.，Innate immune response to arenaviral infection: a focus on the highly pathogenic New World hemorrhagic arenaviruses，J Mol Biol.，2013年，425(24)，4893-903 |
| MOLOMUT, Norman and PADNOS, Morton，INHIBITION OF TRANSPLANTABLE AND SPONTANEOUS MURINE TUMOURS BY THE M-P VIRUS，NATURE，英国，1965年12月04日，VOL:208, NR:5014，PAGE(S):948 - 950，http://dx.doi.org/10.1038/208948a0 |
| Nature Communications，2017年03月01日，8:14447，p. 1-14 |
| Nature，2001年，vol. 411，p. 1058-1064 |
| REISEROVA L; ET AL，IDENTIFICATION OF MATU-MX AGENT AS A NEW STRAIN OF LYMPHOCYTIC CHORIOMENINGITIS VIRUS (LCMV) AND SEROLOGICAL INDICATION OF HORIZONTAL SPREAD OF LCMV IN HUMAN POPULATION，VIROLOGY，NL，1999年04月25日，VOL:257, NR:1，PAGE(S):73 - 83，http://dx.doi.org/10.1006/viro.1999.9638 |
| WEBB, H.E. ET AL.，THE TREATMENT OF 18 CASES OF MALIGNANT DISEASE WITH AN ARENAVIRUS，CLINICAL ONCOLOGY，英国，1975年06月，VOL:1, NR:2，PAGE(S):157-169，https://www.ncbi.nlm.nih.gov/pubmed/1183104 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN108025054A (zh) | 2018-05-11 |
| CA2982873A1 (en) | 2016-10-20 |
| US12409217B2 (en) | 2025-09-09 |
| EP3283104A1 (de) | 2018-02-21 |
| JP7273102B2 (ja) | 2023-05-12 |
| DE102015207036A1 (de) | 2016-10-20 |
| CN108025054B (zh) | 2022-12-23 |
| US20190151436A1 (en) | 2019-05-23 |
| ES3017684T3 (en) | 2025-05-13 |
| EP3283104C0 (de) | 2024-12-11 |
| US20180117137A1 (en) | 2018-05-03 |
| WO2016166285A1 (de) | 2016-10-20 |
| BR112017022022A8 (pt) | 2023-03-07 |
| JP2021129589A (ja) | 2021-09-09 |
| BR112017022022A2 (pt) | 2019-01-22 |
| US11801294B2 (en) | 2023-10-31 |
| JP2018515130A (ja) | 2018-06-14 |
| US20240252611A1 (en) | 2024-08-01 |
| EP3283104B1 (de) | 2024-12-11 |
| HK1251168A1 (zh) | 2019-01-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7039037B2 (ja) | 腫瘍の治療および／または阻止において使用するためのアレナウイルス（ａｒｅｎａｖｉｒｕｓｅｓ）、および、（改善された）腫瘍退縮特性（ｔｕｍｏｒ－ｒｅｇｒｅｓｓｉｏｎ ｐｒｏｐｅｒｔｉｅｓ）を有するアレナウイルス（ａｒｅｎａｖｉｒｕｓｅｓ）を産生するための方法 | |
| KR102100092B1 (ko) | 이종 종양-관련 항원들을 발현하는 아데노바이러스 | |
| AU2021224990B2 (en) | Compositions and methods for organ-protective expression and modulation of coding ribonucleic acids | |
| US20250122244A1 (en) | Method for producing an antitumoral arenavirus as well as arenavirus mutants | |
| BR112017022022B1 (pt) | Uso de um vírus da coriomeningite linfocítica (lcmv) ou um vírus junin e composição compreende os mesmos | |
| HK1251168B (en) | Arenavirus for use in treatment of tumors in human | |
| HK40054624A (en) | Method for producing an antitumoral arenavirus as well as arenavirus mutants | |
| Goswami et al. | Using Oncolytic Viruses to Silence the Multidrug Resistance Genes via RNA Interference | |
| CN111407891A (zh) | 新型自噬受体ccdc50作为靶点在制备治疗病原体感染或癌症的药物中的应用 | |
| HK40054624B (zh) | 用於制备抗肿瘤沙粒病毒的方法以及沙粒病毒突变体 | |
| HK1205182B (en) | Adenoviruses expressing heterologous tumor-associated antigens |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20190325 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20190328 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20190325 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190412 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190412 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20200129 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200206 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20200501 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20200701 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200805 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20210107 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20210128 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210527 |
|
| C60 | Trial request (containing other claim documents, opposition documents) |
Free format text: JAPANESE INTERMEDIATE CODE: C60 Effective date: 20210527 |
|
| C11 | Written invitation by the commissioner to file amendments |
Free format text: JAPANESE INTERMEDIATE CODE: C11 Effective date: 20210607 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210706 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20210707 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20210818 |
|
| C21 | Notice of transfer of a case for reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C21 Effective date: 20210819 |
|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20210820 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20210820 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20211020 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220120 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20220121 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20220224 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20220302 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7039037 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |